Obstet Gynecol Sci.  2021 Mar;64(2):209-215. 10.5468/ogs.20199.

Risk of incidental genital tract malignancies at the time of myomectomy and hysterectomy for benign conditions

• Yadav G
• Rao M
• Goyal SB
• Singh P
• Kathuria P
• Gothwal M

• KMID: 2513950
• DOI: http://doi.org/10.5468/ogs.20199

Abstract

Objective
To determine the incidence of accidentally diagnosed genital malignancies in women undergoing gynecological surgeries for pathologies presumed to be benign.
Methods
Data of all women who underwent hysterectomy for benign indications were retrieved from hospital records. A total of 628 cases of hysterectomy and 35 cases of myomectomy were included. The final histopathology was accessed through the computer records, and the total number of genital tract malignancies was included.
Results
The incidence of occult uterine, ovarian, and cervical malignancies in women undergoing hysterectomy was 0.47%, 0.31%, and 0.15%, respectively. The incidence of uterine corpus malignancies in women undergoing myomectomy was 2.8%, and 3 cases of smooth muscle tumor of uncertain malignant potential (STUMP) were also identified. Endometrial stromal sarcomas were the most common pathology among uterine malignancies, followed by leiomyosarcoma and endometrial adenocarcinoma.
Conclusion
Postoperative diagnosis of malignancies in women undergoing surgery for benign indications poses great challenges to the treating surgeon. Occult malignancies must be ruled out by thorough preoperative assessment, especially in some subsets of women. Morcellation is an inevitable technique and complement to laparoscopic surgeries, although little chances of malignancy spread is related to its use. Nevertheless, thorough preoperative investigations and always ensuring contained morcellation can minimize these chances.

Keyword

Genital neoplasms; Hysterectomy; Myomectomy; Leiomyosarcoma

Reference

References

1. Cohen SL, Vitonis AF, Einarsson JI. Updated hysterectomy surveillance and factors associated with minimally invasive hysterectomy. JSLS. 2014; 18:e201400096.

2. Mahnert N, Morgan D, Campbell D, Johnston C, As-Sanie S. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol. 2015; 125:397–405.

3. Rivard C, Salhadar A, Kenton K. New challenges in detecting, grading, and staging endometrial cancer after uterine morcellation. J Minim Invasive Gynecol. 2012; 19:313–6.

4. U.S. Food and Drug Administration. FDA safety communication UPDATED: laparoscopic uterine power morcellation in hysterectomy and myomectomy. Silver Spring (MD): U.S. Food and Drug Administration;2015. [cited 2020 Jun 30]. Available from: www.bogg.com/custom/images/pdfs/MorcellationNoticeFDA04-17-2014.pdf .

5. Ramm O, Gleason JL, Segal S, Antosh DD, Kenton KS. Utility of preoperative endometrial assessment in asymptomatic women undergoing hysterectomy for pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct. 2012; 23:913–7.

6. Pritts EA, Vanness DJ, Berek JS, Parker W, Feinberg R, Feinberg J, et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol Surg. 2015; 12:165–77.

7. Hill AJ, Carroll AW, Matthews CA. Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicosacropexy for uterine prolapse. Female Pelvic Med Reconstr Surg. 2014; 20:113–5.

8. Liu FW, Galvan-Turner VB, Pfaendler KS, Longoria TC, Bristow RE. A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. Am J Obstet Gynecol. 2015; 212:717–24.

9. Desai VB, Wright JD, Schwartz PE, Jorgensen EM, Fan L, Litkouhi B, et al. Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications. Obstet Gynecol. 2018; 131:642–51.

10. White MP, Rahimi S, Garely A, Buhl A, Dean RM. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): review of pathophysiology, classification, diagnosis, treatment, and surveillance. J Healthc Commun. 2017; 2:40.

11. Şahin H, Karatas F, Coban G, Özen Ö, Erdem Ö, Onan MA, et al. Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes. J Gynecol Oncol. 2019; 30:e54.

12. Gadducci A, Zannoni GF. Uterine smooth muscle tumors of unknown malignant potential: a challenging question. Gynecol Oncol. 2019; 154:631–7.

13. Mowers EL, Skinner B, McLean K, Reynolds RK. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice. J Minim Invasive Gynecol. 2015; 22:601–6.

14. Ganesan R. Uterine smooth muscle tumour of uncertain malignant potential (STUMP): where are we now? Case Rep Womens Health. 2020; 26:e00176.

15. Frick AC, Walters MD, Larkin KS, Barber MD. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. Am J Obstet Gynecol. 2010; 202:507.e1–4.

16. Ackenbom MF, Giugale LE, Wang Y, Shepherd JP. Incidence of occult uterine pathology in women undergoing hysterectomy with pelvic organ prolapse repair. Female Pelvic Med Reconstr Surg. 2016; 22:332–5.

17. Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, et al. Cryo-preservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril. 2011; 95:2158–61.